Healthcare / Medical DevicesTaipei Exchange
$176.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-6.7M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.2B
P/E
262.7x
↑EV/EBITDA
27.9x
↑ROE
1.8%
↑Gross Margin
27.7%
↓Debt/Equity
1.05
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.5%
FCF CAGR
—
FCF margin
11.5%
FCF / Net income
3.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $694.2M · net income $23.4M · FCF $79.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $694.2M | $694.2M | $580.5M | $508.0M | $463.0M |
| Net Income | $23.4M | $23.4M | $57.2M | $85.8M | $171.3M |
| EBITDA | $265.5M | $265.5M | $247.0M | $187.4M | $278.1M |
| EPS | — | — | 1.63 | 2.44 | 4.87 |
| Gross Margin | 27.7% | 27.7% | 24.1% | 41.1% | 50.5% |
| Operating Margin | 8.5% | 8.5% | 6.5% | 21.7% | 28.8% |
| Net Margin | 3.4% | 3.4% | 9.9% | 16.9% | 37.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.05 | 1.05 | 1.34 | 1.33 | 0.43 |
| Current Ratio | 0.53 | 0.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $79.5M | $79.5M | $-6.7M | $-1.08B | $-466.4M |
| Returns | |||||
| ROE | 1.8% | 1.8% | 4.4% | 6.9% | 14.5% |
| Valuation | |||||
| P/E | 262.69 | 262.69 | 143.77 | 80.37 | 34.95 |
| EV/EBITDA | 27.88 | 27.88 | 39.11 | 43.65 | 22.13 |
| P/B | 4.71 | 4.71 | 6.38 | 5.58 | 5.08 |
| Growth & Yield | |||||
| Revenue Growth | 19.6% | 19.6% | 14.3% | 9.7% | — |
| EPS Growth | — | — | -33.3% | -49.8% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.9%
Start / end P/E
n/dx → n/dx
EPS bridge
1.63 → n/d
Residual
-25.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.